David L. Keenan

David has over 16 years of experience in the development and deployment of complex active cardiovascular implants. He was actively involved in the development of the AngelMed Guardian system from the start and participated in the first in man implant in Brazil, and the first implants in the US and Germany.

Dave took over responsibility for the ALERTS Clinical Study in 2012 and then oversaw the analysis and reporting of efficacy and safety results for the PMA submission, including the amendment that led to FDA approval. Dave has a dozen patents related to medical devices and computer networking technologies.

Prior to Angel Medical, Dave was a Director at Corente, Inc. (formally OpenReach), a leader in managed secure networks. At OpenReach, Dave managed the provisioning and support of networks in 40 countries. Before joining Corente, Dave spent 15 years at AT&T Bell Laboratories. During that time, Dave worked within the R&D team that created Ethernet over twisted pair wire. Dave traveled to over 44 countries during this period to support and troubleshoot network problems for AT&T and NCR. Prior to AT&T, Dave worked in R&D for Perkin Elmer Corporation on some of the world’s first 32-bit minicomputers, used to power state of the art military simulators. Dave’s first job after graduating from The Catholic University of America was in the Inhalation Toxicology Labs of Hazleton Laboratories in Reston, Virginia. This lab was the setting for the best seller “The Hot Zone” which chronicled the early discoveries associated with the ebola virus.